Sanofi Consumer Healthcare India Q2 2026: ₹235.7 crore

What the company filed and why it matters

Sanofi Consumer Healthcare India Limited has submitted an intimation on the publication of its unaudited financial results for the quarter and half-year ended June 30, 2026. The company said the notice of financial results was published in Business Standard and Sakal on July 30, 2026. The update is a routine regulatory compliance under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. Such filings are aimed at ensuring that material information, including the public release of financial performance data, is disclosed and broadly accessible. For investors tracking listed consumer healthcare names, this type of confirmation helps validate when and where the results were made public.

Board approval and limited review details

The company said its Board of Directors, in a meeting held on July 28, 2026, approved the unaudited financial results for the quarter and half-year ended June 30, 2026. It also submitted the results along with a Limited Review Report from its statutory auditors, Price Waterhouse & Co Chartered Accountants LLP, under the SEBI Listing Regulations. The filing noted that the results would be published in newspapers and would also be made available on the company’s investor website. The board meeting began at 4:00 p.m. and concluded at 6:00 p.m., as per the disclosure. Limited reviews are common for interim results and are distinct from a full statutory audit.

Q2 FY2026 performance: revenue and profit movement

For the quarter ended June 30, 2026, Sanofi Consumer Healthcare India reported revenue from operations of ₹235.7 crore, a 7% year-on-year increase. Profit before tax (PBT) rose 16% year-on-year to ₹91.9 crore. Profit for the period stood at ₹68.8 crore, compared with ₹60.7 crore in the corresponding quarter of the previous year. The company also reported earnings per share (EPS) of ₹29.87 for the quarter. The results, as presented in the release, emphasise both topline expansion and faster growth in profit before tax.

Half-year (H1) numbers disclosed

For the half-year ended June 30, 2026, the company reported profit for the period of ₹136.6 crore. In the detailed earnings summary, the six-month net income was also stated at ₹136.6 crore compared with ₹110.7 crore a year ago. Over the same period, sales were reported at ₹464.9 crore versus ₹393.5 crore a year earlier, while revenue was ₹476.8 crore versus ₹404.3 crore. The six-month EPS was disclosed at ₹59.31, compared with ₹48.07 in the year-ago period.

Brand relaunches cited as a business driver

The company attributed Q2 performance support to the relaunch of key brands, naming Combiflam, Allegra, and Depura. While the filing does not quantify the contribution of individual products, it links the quarterly revenue outcome to brand activity. For consumer healthcare businesses, relaunch cycles typically involve refreshed positioning, distribution pushes, and promotional resets. Investors often look for signs that such interventions are translating into sustained revenue execution rather than one-off quarter impacts. In this update, the linkage is stated in broad terms, without segment-level splits.

Snapshot of key reported metrics

Publication and disclosure trail

The company confirmed that the financial results notice was published on July 30, 2026, in Business Standard and Sakal. This kind of newspaper publication is part of the broader disclosure framework that complements stock exchange filings. Alongside the publication confirmation, the company stated that the results would be accessible on its investor website. The sequence described in the disclosures is consistent with how interim results are typically approved by the board, reviewed by auditors (limited review), filed with exchanges, and then published.

Additional context: prior board meeting disclosure

Separately, the provided information also refers to an earlier intimation where the company informed BSE that a board meeting was scheduled on April 28, 2026 to consider and approve unaudited financial results for the quarter ended March 31, 2026. It also stated that the audit committee and board approved those results at their meetings held on April 28, 2026, and that a limited review report and unaudited financial results were enclosed as required under Regulation 33 of the SEBI Listing Regulations. This background indicates a continuing pattern of timely, process-driven disclosures around interim financial reporting.

Global Sanofi update included in the release material

The text also contains a separate update from Sanofi at the group level dated July 30, 2026, referring to Q2 2026 sales growth and an upgraded 2026 guidance. In that update, Q2 net sales were reported at €11,597m, and business EPS at €2.09. The same material also referenced product-level performance, including Dupixent sales of €5.2 billion and vaccines sales of €1.1 billion. These figures are presented as part of the parent group’s broader financial communication and are distinct from the India consumer healthcare entity’s rupee-denominated results.

Market impact and what investors can verify today

From a market information standpoint, the key development is not just the quarter’s reported revenue and profit, but the confirmation that results were approved, reviewed, filed, and published through recognised channels. Investors can verify the quarter’s core metrics from the disclosed numbers: revenue from operations of ₹235.7 crore, PBT of ₹91.9 crore, and profit for the period of ₹68.8 crore, alongside EPS of ₹29.87. For the half-year, the company has disclosed profit of ₹136.6 crore and EPS of ₹59.31, plus sales and revenue values in the ₹460 crore to ₹480 crore range. The company has also named the auditor involved in the limited review, which is relevant for assessing procedural completeness.

Conclusion

Sanofi Consumer Healthcare India’s filing confirms the public release of its unaudited Q2 and H1 results for the period ended June 30, 2026, and documents where the statutory notice was published. The company reported Q2 revenue from operations of ₹235.7 crore and profit of ₹68.8 crore, with half-year profit of ₹136.6 crore. Next milestones for investors are typically the company’s subsequent periodic financial updates and any further disclosures posted to the exchange and its investor website.